Table 4

The Jundiaí Zika cohort, summary of health, medical and laboratory data collected from women and their children

PhaseMeasurements
Pregnant women at enrolmentBaseline questionnaire - sociodemographic details, past medical history, family history, past obstetric history (parity, miscarriages, mode of delivery, malformations), current obstetric history (if pregnancy was planned, use of tobacco, alcohol, drug and medications and vaccinations received), presence of symptoms/signs consistent with ZIKV infection (fever, rash, non-purulent conjunctivitis, arthritis/arthralgia, lymphadenopathy, myalgia, headache) at any point throughout pregnancy, the woman’s environment (type of housing, number of rooms, number of people per household), preventative measures (use of repellent, protective clothing, window or bed nets, barrier contraception) and their knowledge of ZIKV and its forms of transmission as well as what their sources of information were
Pregnant women follow-up 14–21 days after enrolmentSample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM
Symptoms questionnaire - presence of symptoms/signs consistent with ZIKV infection (timing, duration, intensity, action taken)
Pregnant women subsequent 2–3 monthly follow-upsSample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM
Symptoms questionnaire - presence of symptoms/signs consistent with ZIKV infection (timing, duration, intensity, action taken)
Antenatal ultrasound at São Paulo foetal medicine centre
Pregnant women weekly phone follow-upSymptoms questionnaire - presence of symptoms/signs consistent with ZIKV infection (timing, duration, intensity, action taken)
Birth (mother and neonate)Sample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM. Colostrum (mother) and cerebrospinal fluid (neonate exposed to ZIKV and/or with microcephaly) for ZIKV PCR.
Anthropometry – weight, length, head circumference (neonate)
Placenta and umbilical collection - pathology
Neonatal, infant and child follow-upsSample collection (blood, saliva, urine) for ZIKV RT-PCR and IgG/IgM in months 1, 3, 6 and 15 for neonates. (Women found to be ZIKV RT-PCR positive during pregnancy also had blood, saliva and urine collected during paediatric follow-up appointments).
Paediatric follow-up questionnaire – problems, significant events, feeding, vaccinations, developmental milestones reached, review of lab test results (including heel-prick test)
Anthropometry – weight, length, head circumference
Paediatric physical examination – general, cardiovascular, respiratory, gastrointestinal, neurological, developmental
Physiotherapy assessment
Speech and language assessment
ZIKV exposed infants and/or with microcephaly/other neurological abnormalitiesOpthalmology assessment (with Teller-CAT Cambridge Colour Test, funduscopy and extrinsic ocular motility tests)
Specialist neurodevelopmental assessment (using Bayley-III developmental scales)
Specialist audiology assessment
Gastrointestinal assessment
Imaging – Cranial ultrasound and CT brain at birth and 12 months
  • PCR, polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction; ZIKV, Zika virus.